Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Procept Biorobotics Corp

Healthcare US PRCT

27.56USD
0.56(2.07%)

Last update at 2026-06-05T18:14:00Z

Day Range

26.5927.57
LowHigh

52 Week Range

47.04103.81
LowHigh

Fundamentals

  • Previous Close 27.00
  • Market Cap3212.94M
  • Volume420924
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-90.87800M
  • Revenue TTM249.12M
  • Revenue Per Share TTM4.69
  • Gross Profit TTM 156.23M
  • Diluted EPS TTM-1.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -87.15400M -59.85300M -53.01900M -41.97500M
Minority interest - - - -
Net income -93.58400M -62.38400M -58.25500M -42.65300M
Selling general administrative 88.83M 51.04M 30.27M 28.52M
Selling and marketing expenses - - - -
Gross profit 37.09M 15.87M -1.25500M -1.88500M
Reconciled depreciation 2.84M 3.32M 2.86M 1.49M
Ebit -80.72400M -54.16400M -47.80200M -43.55000M
Ebitda -78.71300M -54.04300M -44.78300M -40.95300M
Depreciation and amortization 2.01M 0.12M 3.02M 2.60M
Non operating income net other - 0.12M - -
Operating income -80.72400M -54.16400M -47.80200M -43.55000M
Other operating expenses 155.74M 88.64M 55.52M 49.72M
Interest expense 5.18M 5.81M 5.26M 0.72M
Tax provision - - - -
Interest income 2.50M 0.12M 0.18M 1.15M
Net interest income -2.68600M -5.68900M -5.07700M 0.42M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 6.43M 2.53M 5.24M 0.68M
Total revenue 75.01M 34.47M 7.72M 6.17M
Total operating expenses 117.81M 70.03M 46.55M 41.66M
Cost of revenue 37.93M 18.61M 8.97M 8.05M
Total other income expense net -6.43000M -5.68900M -5.21700M 1.57M
Discontinued operations - - - -
Net income from continuing ops -87.15400M -59.85300M -53.01900M -41.97500M
Net income applicable to common shares -87.15400M -59.85300M -53.01900M -41.97500M
Preferred stock and other adjustments - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 534.02M 404.72M 309.33M 337.02M 125.97M
Intangible assets 0.93M 1.20M 1.48M 1.75M -
Earning assets - - - - -
Other current assets 8.45M 5.21M 6.17M 4.24M 0.73M
Total liab 131.80M 123.97M 112.26M 69.93M 308.87M
Total stockholder equity 402.22M 280.75M 197.07M 267.09M -182.89400M
Deferred long term liab - - - 1.50M -
Other current liab 29.56M 25.09M 20.91M 11.08M 6.79M
Common stock - - - -337.02400M -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -545.98500M -454.57200M -348.67500M -261.52100M -201.66800M
Other liab - - - 0.20M 0.20M
Good will - - - - -
Other assets - 0.00000M 3.09M 0.78M 0.78M
Cash 333.73M 257.22M 221.86M 304.32M 100.13M
Cash and equivalents - - - - -
Total current liabilities 53.13M 45.93M 35.29M 16.24M 14.53M
Current deferred revenue 9.56M 5.66M 2.85M 1.02M 0.23M
Net debt -253.47500M -178.01800M -144.54200M -250.22000M -45.36800M
Short term debt 1.91M 1.68M 2.13M 2.10M 6.26M
Short long term debt - - - - 4.55M
Short long term debt total 80.25M 79.20M 77.32M 54.10M 54.76M
Other stockholder equity 948.21M 735.24M 545.75M 191.64M 18.79M
Property plant equipment - - 32.14M 8.32M 12.91M
Total current assets 481.84M 350.57M 272.63M 326.17M 110.26M
Long term investments - - - - -
Net tangible assets - - 195.59M 265.34M -184.91700M
Short term investments - - - - -
Net receivables 83.50M 48.38M 15.27M 4.46M 1.55M
Long term debt 51.47M 51.34M 51.21M 50.00M 44.41M
Inventory 56.17M 39.76M 28.54M 13.15M 7.48M
Accounts payable 10.03M 13.50M 9.39M 2.03M 1.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.08M -0.00600M -0.05300M -0.01400M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -261.52100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.59M 0.92M 3.09M 0.78M 0.78M
Deferred long term asset charges - - - - -
Non current assets total 52.17M 54.15M 36.70M 10.85M 15.71M
Capital lease obligations 28.78M 27.86M 26.10M 4.10M 5.80M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2.65300M -0.59200M -0.23300M 50.76M
Change to liabilities 5.79M 6.17M -0.07800M -0.48700M
Total cashflows from investing activities -2.65300M -0.59200M -0.23300M 43.15M
Net borrowings 1.20M 1.20M 24.68M 24.53M
Total cash from financing activities 3.61M 262.12M 106.77M 26.53M
Change to operating activities 8.78M 2.73M 3.21M 1.51M
Net income -87.15400M -59.85300M -53.01900M -41.97500M
Change in cash -79.42300M 204.19M 58.20M 25.86M
Begin period cash flow 305.10M 100.91M 42.71M 16.85M
End period cash flow 225.67M 305.10M 100.91M 42.71M
Total cash from operating activities -80.38200M -57.33400M -48.34300M -43.81800M
Issuance of capital stock 0.00000M 257.07M 76.49M 0.00000M
Depreciation 2.84M 3.32M 2.86M 1.49M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -15.25100M -6.12400M -3.10500M -5.07400M
Change to account receivables -10.80900M -2.91400M -0.51100M 0.52M
Sale purchase of stock 2.41M 177.41M - -
Other cashflows from financing activities 50.20M 89.75M -0.23300M 43.15M
Change to netincome 15.42M 4.45M 2.30M 0.20M
Capital expenditures 2.65M 0.59M 0.23M 7.61M
Change receivables - -2.91400M - -
Cash flows other operating - -2.38300M - -
Exchange rate changes - - - -
Cash and cash equivalents changes - 204.19M - -
Change in working capital -11.48700M -4.70700M -0.48300M -3.53200M
Stock based compensation 10.34M 3.80M 2.17M 1.99M
Other non cash items 5.08M -0.34500M -0.09700M -1.79900M
Free cash flow -83.03500M -57.92600M -48.57600M -51.42900M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRCT
Procept Biorobotics Corp		 0.56 2.07% 27.56 - - 12.90 8.26 11.96 -24.5778
ABT
Abbott Laboratories		 0.86 0.95% 91.64 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 6.17 2.05% 307.38 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.26 0.32% 81.67 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.12 0.24% 48.97 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Procept Biorobotics Corp

150 Baytech Drive, San Jose, CA, United States, 95134

Key Executives

Name Title Year Born
Dr. Reza Zadno Ph.D. Pres, CEO & Director 1955
Mr. Kevin Waters Exec. VP & CFO 1977
Mr. Hisham Shiblaq Exec. VP & Chief Commercial Officer 1976
Mr. Mohan F. Sancheti Sr. VP of Operations 1964
Ms. Alaleh Nouri EVP, Chief Legal Officer & Corp. Sec. 1979
Ms. Minni Vittal Sr. VP & Chief People Officer NA
Mr. Bijesh Chandran Sr. VP of Regulatory Affairs & Quality Assurance NA
Mr. Barry Templin Sr. VP of Clinical & Medical Affairs NA
Dr. Thomas J. Yorkey Ph.D. Sr. VP of R&D 1962
Dr. Reza Zadno Ph.D. President, CEO & Director 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions